Paris startup baCta raises €7 million for microbial manufacturing
Paris-based biotech startup baCta has secured a €7 million funding round to advance its vision of using microorganisms as programmable molecular factories for the production of industrial ingredients. The fresh capital will help the company scale its platform, expand its team and move closer to commercial deployments with industrial partners.
Microorganisms as programmable factories
baCta is developing a technology platform that treats microbes as reconfigurable production units. By engineering and optimizing their metabolic pathways, the company aims to program microorganisms to manufacture high-value compounds more efficiently and sustainably than traditional chemical processes.
The approach leverages advances in synthetic biology, metabolic engineering and bioprocess automation. Instead of relying on petrochemical routes or resource-intensive extraction from plants, baCta grows customized microbes in controlled fermentation systems to produce ingredients for sectors such as food, cosmetics, materials and specialty chemicals.
Targeting industrial ingredients and sustainability
Industrial manufacturers are under pressure to cut emissions, reduce waste and secure more resilient supply chains. baCta positions its platform as a way to replace or complement conventional production with bio-based routes that use fewer resources and generate fewer by-products.
By fine-tuning microbial strains and process conditions, the startup aims to deliver consistent quality at competitive cost, while enabling new molecules that are difficult or uneconomical to synthesize using classic chemistry. This capability is particularly relevant for functional ingredients, performance additives and niche compounds where traditional manufacturing faces technical or economic barriers.
Scaling up and industrial partnerships
The €7 million injection will be used to strengthen baCta‘s R&D infrastructure, expand its library of engineered strains and accelerate pilot-scale production. The company is also expected to deepen collaborations with industrial players seeking to decarbonize their portfolios and differentiate products through advanced bio-based ingredients.
As global demand grows for cleaner manufacturing solutions, platforms that harness microorganisms as programmable molecular factories are drawing increasing interest from both investors and corporates. baCta‘s latest funding round underscores the momentum behind this new wave of industrial biotechnology in Europe.